Possible new combination treatment for cancer

June 19, 2014
This image depicts Jonas Nilsson of the Sahlgrenska Cancer Center at the University of Gothenburg. Credit: The University of Gothenburg

Scientists at the Sahlgrenska Academy have developed a new cancer treatment that has proved to be effective in mice. The treatment, which is presented in the prestigious scientific journal PNAS, is based on newly discovered properties of the so-called BET bromodomain inhibitors.

A few years ago, a molecule known as "JQ1" was developed, which can block so called BET bromodomain proteins. This switch off the known cancer gene MYC thereby preventing from dividing.

The discovery was regarded as a major breakthrough. A problem was that JQ1 did not function optimally in animal experiments, and this means that it has not been possible to test the on cancer patients.

New molecule

Jonas Nilsson and his research group have developed, in collaboration with the Canadian company Zenith epigenetics, a new molecule known as "RVX2135", which has been tested in mice with MYC-driven lymphoma. The study will be published this week in the early edition of the prestigious scientific journal PNAS and shows that the new molecule not only causes cancer cells in culture to stop growing, it also causes tumors to die. This means that the mice survive their cancer longer.

"We hypothesized that the new molecule could also switch off the MYC gene. However, our studies show that neither the JQ1 molecule nor the RVX2135 molecule have this property in these types of cells. This means that the mode of action is probably not as simple as we believed," says Jonas Nilsson, Group Leader at the Sahlgrenska Cancer Center.

Increased survival in mice

The scientists in Gothenburg also discovered that the RVX2135 molecule activates the same genes as those activated by molecules known as "HDAC inhibitors", which are already used to treat . The scientists then tested HDAC inhibitors together with the newly discovered and it turned out that the combination increased survival in mice with lymphoma.

"It was also possible to reduce the dose of HDAC inhibitors when used in combination with RVX2135 and this reduced adverse effects. We see this as a breakthrough in the clinical development of this type of treatment," Jonas Nilsson explains.

Further development

Jonas Nilsson has recently founded the Sahlgrenska Translational Melanoma Group together with surgeons and oncologists at the Sahlgrenska University Hospital. This group will investigate whether the treatment can be used also for malignant melanoma.

"The work is challenging, but we believe that the prospects for success with combination treatments are good," says Jonas Nilsson.

Explore further: Novel approach scores first success against elusive cancer gene

More information: www.pnas.org/content/early/2014/06/13/1406722111.abstract

Related Stories

Novel approach scores first success against elusive cancer gene

September 9, 2011

Dana-Farber Cancer Institute scientists have successfully disrupted the function of a cancer gene involved in the formation of most human tumors by tampering with the gene's "on" switch and growth signals, rather than targeting ...

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.